Catalyst Wire Dossier Catalyst Wire Dossier

Makena® (hydroxyprogesterone caproate injection, 250 mg/mL)

hydroxyprogesterone caproate · AMAG Pharmaceuticals, Inc.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Makena® (hydroxyprogesterone caproate injection, 250 mg/mL), covering 2018-11-30 to 2018-11-30. Get the full timeline:

Most recent: Clinical Trial Update: Comparing Bioavailability When Preservative-free Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) is Administered as an Intramuscular Manual Injection or as a Subcutaneous Injection Using an Auto-injector in Healthy Post-menopausal Women [Phase 1]

See pricing